IP Library › Granted Patent US 7,968,565
Granted Patent B2
US 7,968,565 · App. 11/080,102 · Granted Jun 28, 2011

Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,565
App. No.
11/080,102
Granted
Jun 28, 2011
Kind
B2
Abstract

The present invention relates to SNS-595 and methods of treating cancer using the same.

Claims (1)

1. A combination comprising: a) a therapeutically effective amount of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and b) a therapeutically effective amount of cytarabine.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 5, 2020
From: WESTERN ALLIANCE BANK
To: SUNESIS PHARMACEUTICALS, INC.
Reel/Frame 054335/0429 →
SECURITY INTEREST Recorded May 10, 2016
From: SUNESIS PHARMACEUTICALS, INC.
To: WESTERN ALLIANCE BANK
Reel/Frame 038655/0493 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2016
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: SUNESIS PHARMACEUTICALS, INC.
Reel/Frame 038330/0382 →
SECURITY AGREEMENT Recorded May 7, 2012
From: SUNESIS PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 028169/0528 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2005
From: ARKIN, MICHELLE; HYDE, JENNIFER; WALKER, DUNCAN; WRIGHT, JASMIN
To: SUNESIS PHARMACEUTICALS, INC.
Reel/Frame 016706/0201 →